| Biomarker ID | 1821 |
| PMID | 30610587 |
| Year | 2018 |
| Biomarker | AMBP; (cDNA FLJ50830, highly similar to AMBP); (unnamed protein product); (Isoform 2 of Calmodulin-regulated spectrin-associated protein 1-like 1 (CAMSAP1L1); cDNA FLJ51445, highlysimilar to AMBP protein; Ribosomal RNA upstream binding transcription factor (Fragment, UBTF); Basementmembrane-specific heparan sulfate proteoglycan coreprotein (HSPG2); Ferritin heavy chain (FTH1); Transthyretin; 13 kDa protein; Unknown (protein for IMAGE:3934797); Putative beta-actin-like protein 3 F7 Factor VII active sitemutant immunoconjugate; C11orf54 Aminoacylase-1 (ACY1); Ferritin Light chain (FTL) Coactosin-like protein (COTL1); |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Urine |
| Subjects | Humans |
| Regulation | Methylated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Controls and Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 3 patients from each group: PCa, BPH; Controls were selected for analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | MALDI-TOF-MS |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |